Lannett Company Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Dive Deeper Into the Growth Paths Behind the Analysis
This Lannett Company Balanced Scorecard Analysis gives you a clear, structured view of the company's financial, customer, internal process, and learning and growth priorities. The page already shows a real preview of the actual analysis, so you can review the content before buying. Purchase the full version to get the complete ready-to-use report.
Benefits
Margin Discipline
A balanced scorecard keeps Lannett Company focused on gross margin per SKU, yield, and scrap, which is crucial when generic pricing can swing fast. In FY2025, that discipline matters across both generic prescription products and contract manufacturing, where even a 1% yield lift or scrap cut can protect cash. It turns margin control into a weekly operating metric, not a year-end surprise.
Quality Control
Quality control turns FDA compliance, deviations, CAPA closure, and complaint trends into clear management signals, so Lannett Company can spot plant risk fast. In a regulated network, that helps cut batch holds and rework; FDA data show 2025 Form 483 observations often cite inadequate procedures and failure investigations, the same issues QC should surface early. Faster CAPA closure also protects throughput and lowers scrap, which matters when one delayed batch can ripple through supply.
Delivery Reliability
For Lannett Company, delivery reliability means tracking on-time shipment and fill rate so buyers get steady supply in generic drugs and contract manufacturing. In 2025, even one missed order can matter because customers can switch suppliers fast, so better fill rates help protect repeat business and reduce lost sales. If service slips, trust drops quickly; if shipments land on time, buyer relationships hold.
Portfolio Prioritization
Portfolio prioritization helps Lannett Company rank cardiovascular, CNS, and pain management products by volume, margin, and service load, so capital goes to the mix that earns the best return. In a balanced scorecard, that makes launch timing clearer and cuts weak pipeline bets. It also links commercial demand to supply capacity, which matters when one portfolio can carry the business faster than another.
Working Capital
Working capital is a high-value lens for Lannett Company because low-margin pharma can tie up cash in stock and receivables fast. The scorecard should track inventory turns, receivable days, and release cycle time; cutting 10 days from cash conversion can free meaningful cash when gross margins are thin.
It also flags slow-moving lots before they age out, which helps protect margin and avoid write-downs.
Lannett's FY2025 Margin, Quality, and Cash Boost
For Lannett Company, the biggest benefit is tighter control of margin, quality, and cash in FY2025, where even a 1% yield gain or scrap cut can protect profit. A scorecard also improves FDA readiness, on-time fill, and portfolio mix. Cutting 10 days from cash conversion can free cash fast.
| Metric | FY2025 benefit |
|---|---|
| Yield and scrap | Protect margin |
| On-time fill rate | Protect repeat sales |
| Cash conversion | Free working capital |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Price Pressure
Price pressure is a real drawback for Lannett Company because a balanced scorecard can show smoother output, higher fill rates, or better quality while generic drug ASPs keep falling. In fiscal 2025, that kind of erosion can cut gross profit even when operating metrics look stable, so the scorecard may overstate health. The risk is simple: good process scores do not stop buyers and competitors from pushing prices down.
Data Fragmentation
In fiscal 2025, Lannett Company's quality, plant, finance, and commercial data can still sit in separate systems, so one monthly scorecard may pull from four different inputs. That slows close, raises rework, and can make one metric look better or worse than it is. For a narrow-margin generic drug maker, even a small delay in spotting yield, recall, or revenue drift can hurt decisions fast.
Validation Lag
Validation lag is a real drag on Lannett Company's scorecard because pharma process changes must be tested, documented, and approved before they count in output. That means KPI targets can shift in one quarter, while manufacturing gains show up much later in batch release, yield, and deviation rates. If management pushes faster than validation allows, the scorecard can overstate progress and hide the true cost of change.
Thin Differentiation
Lannett Company's thin differentiation is a real drawback: in FY2025, the U.S. generic drug market still filled about 90% of prescriptions, but price competition kept value capture low. Balanced scorecard discipline can improve cost, quality, and delivery, yet it does not create brand power or patent walls. For a generic maker, that means operational gains often improve efficiency more than pricing or long-term margin expansion.
Customer Concentration
Customer concentration can make Lannett Company's scorecard look stronger than it is if a few buyers or contract manufacturing accounts drive most volume. When one order slips, throughput and line utilization can drop fast, and fixed plant costs then weigh harder on margin. In a year like fiscal 2025, that kind of mix risk matters more than a single KPI, because one lost account can distort revenue, cash flow, and operating leverage at once.
The balanced scorecard should flag customer share, order renewal risk, and revenue by account, not just total sales.
Lannett's FY2025 Weak Spot: Falling ASPs, Split Data, Thin Margins
Lannett Company's main drawback in fiscal 2025 is that a balanced scorecard can look healthy while ASPs, customer mix, and margin still weaken. For a low-margin generic maker, validation delays and split data flows also make KPI timing lag real business damage.
| Drawback | FY2025 signal |
|---|---|
| Price pressure | APs keep falling |
| Data silos | 4 input streams |
| Market power | About 90% U.S. scripts are generic |
What You See Is What You Get
Lannett Company Reference Sources
This preview shows the actual Lannett Company Balanced Scorecard Analysis document you'll receive after purchase – no samples, no placeholders, just the real file. The full report is available immediately after checkout. You're viewing the same professional content that will be delivered in your download.
Frequently Asked Questions
It highlights whether a low-margin generic drug maker is executing on quality, cost, and delivery at the same time. For Lannett, the most useful indicators are batch yield, on-time shipment, FDA quality findings, and gross margin across its 3 therapeutic areas and 2 business lines. That combination shows if operations are translating into cash.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.